We are live on ! Find out more
VINC

Vincerx Pharma, Inc. Common Stock
VINC

Delisted

VINC was delisted on the 22nd of April, 2025.

Back to rankings

32 hedge funds and large institutions have $11.7M invested in Vincerx Pharma, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $10.8M → $11.7M (+$819K)

6% less funds holding

Funds holding: 34 → 32 (-2)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
32
Holders Change
-2
Holders Change %
-5.88%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MG
Marex Group
+$41.5K
2
Renaissance Technologies
Renaissance Technologies
New York
+$36.2K
3
Citadel Advisors
Citadel Advisors
Florida
+$24K
4
Morgan Stanley
Morgan Stanley
New York
+$8.99K
5
Wells Fargo
Wells Fargo
California
+$17

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$311K
2
Goldman Sachs
Goldman Sachs
New York
-$297K
3
CC
Clearline Capital
New York
-$99.9K
4
SM
Sabby Management
Florida
-$57.9K
5
ECM
ExodusPoint Capital Management
New York
-$55K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$2.02M -$297K -17,663 -17%
SRC
2
Sage Rhino Capital
California
$2.01M – – –
LFCM
3
Long Focus Capital Management
Puerto Rico
$1.3M – – –
Bank of America
4
Bank of America
North Carolina
$1.28M -$311K -18,502 -25%
RSCM
5
Rock Springs Capital Management
Maryland
$1.05M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$606K – – –
KCM
7
Kingdon Capital Management
New York
$454K – – –
RCMNY
8
Rubric Capital Management (New York)
New York
$418K – – –
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$407K – – –
ECM
10
ExodusPoint Capital Management
New York
$382K -$55K -3,270 -17%
TC
11
Tejara Capital
United Kingdom
$275K – – –
Citadel Advisors
12
Citadel Advisors
Florida
$233K +$24K +1,427 +17%
Renaissance Technologies
13
Renaissance Technologies
New York
$208K +$36.2K +2,156 +32%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$182K – – –
Walleye Capital
15
Walleye Capital
New York
$136K – – –
SSA
16
Schonfeld Strategic Advisors
New York
$135K – – –
SCM
17
Sio Capital Management
New York
$120K – – –
BlackRock
18
BlackRock
New York
$75.8K – – –
MG
19
Marex Group
$58.3K +$41.5K +2,470 New
State Street
20
State Street
Massachusetts
$50.9K – – –
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$48K – – –
T. Rowe Price Associates
22
T. Rowe Price Associates
Maryland
$48K – – –
Morgan Stanley
23
Morgan Stanley
New York
$41.9K +$8.99K +535 +43%
Millennium Management
24
Millennium Management
New York
$40.7K -$2.19K -130 -7%
Northern Trust
25
Northern Trust
Illinois
$30.2K – – –
1
2

VINC Hedge Fund Activity: Q4 2023 in Review

32 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q4 2023, worth a combined $11.7M — up 7.6% from $10.8M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of VINC and 1 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 4 added.

The largest buyer was Marex Group, opening a new position worth an estimated $41.5K. The largest seller was Bank of America, cutting an estimated $311K.

  • 32 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q4 2023, down from 34 in Q3 2023.
  • Funds reported $11.7M of Vincerx Pharma, Inc. Common Stock stock for Q4 2023, up 7.6% quarter-over-quarter.
  • 1 fund opened new Vincerx Pharma, Inc. Common Stock positions in Q4 2023 and 3 closed out, a net change of -2 holders.
  • The largest Vincerx Pharma, Inc. Common Stock buyer in Q4 2023 was Marex Group, an estimated $41.5K added.
  • The largest Vincerx Pharma, Inc. Common Stock seller in Q4 2023 was Bank of America, an estimated $311K sold.

Based on aggregated 13F filings for Q4 2023.